IC
ANVS icon

Ikarian Capital’s Annovis Bio ANVS Stock Holding History

Ikarian Capital’s Portfolio ANVS Stock Details ANVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-517
Closed -$298K – 150
2024
Q2 		$298K Sell
517
-249,483
-100% -$2.02M 0.05% 102
2024
Q1 		$2.98M Buy
+250,000
New +$2.73M 0.33% 74

Other funds holding ANVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
A
AlphaQuest New York $1.79B AUM 10.61% 1-Year Est. Return
WFAG
Wescott Financial Advisory Group Philadelphia, Pennsylvania $1.14B AUM 16.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIAP
Sterling Investment Advisors (Pennsylvania) Berwyn, Pennsylvania $552M AUM 26% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Ikarian Capital's ANVS Position: Q3 2021 in Review

Ikarian Capital sold out of Annovis Bio (ANVS) in Q3 2021, closing a stake of 103,527 shares — an estimated $8.86M sold.

Ikarian Capital first reported a position in ANVS in Q1 2021 and held it in 2 quarters. The position peaked at $8.86M in Q2 2021. 38 funds tracked by Wall St. Rank hold ANVS as of Q3 2021.

  • Ikarian Capital reported no remaining Annovis Bio position as of Q3 2021 after selling out during the quarter.
  • Ikarian Capital sold 103,527 Annovis Bio shares in Q3 2021, an estimated $8.86M.
  • Ikarian Capital first reported a position in Annovis Bio in Q1 2021 and held it in 2 quarters.
  • Ikarian Capital's Annovis Bio position peaked at $8.86M in Q2 2021.
  • 38 funds tracked by Wall St. Rank held Annovis Bio as of Q3 2021.

Based on Ikarian Capital's 13F filing for Q3 2021, filed 15 Nov 2021.